The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline ... but a powerful factor that might influence its near-term stock price is how the actual results compare to these ...

Biogen (NASDAQ:BIIB – Free Report) had its price objective raised by Royal Bank of Canada from $221.00 to $225.00 in a research note issued to investors on Tuesday morning,Benzinga reports.

14 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

Biogen Inc. (BIIB) shares rallied 5.7% in the last trading ... estimate revisions are strongly correlated with near-term stock price movements. For Biogen, the consensus EPS estimate for the ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

SG Americas Securities, LLC has opened a new $98.5M position in $BIIB, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 03-31-2025 ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the May 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...

Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ:BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, ...

In trading on Friday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 27.8, after changing hands as low as $123.02 per share. By comparison ...

As April gives way to May, the market braces for a blockbuster week packed with earnings from some of the biggest names ...